

AOI ONCOLOGY



CHRONICLE

July 2026

Volume 1



**Advancing
Oncology
Through
Expertise &
Evidence**

Inside this issue ▶

FDG PET/CT IN AGGRESSIVE PROSTATE CANCER VARIANTS

The "PSA Paradox": When FDG PET/CT Outperforms Traditional Markers

RARE SARCOMA MANAGED WITH ADAPTIVE CHEMOTHERAPY

Turning the tide in an unresectable case

FLUORESCENCE-GUIDED ROBOTIC ESOPHAGECTOMY

Precision surgery with ICG navigation

FLUORESCENCE-GUIDED ROBOTIC ESOPHAGECTOMY

Precision surgery with ICG navigation

TOTAL BODY IRRADIATION IN BMT CONDITIONING

A new milestone in advanced radiotherapy

AUTOLOGOUS PBSCT IN HIV-POSITIVE MULTIPLE MYELOMA

A case of successful transplant & recovery



15

CLINICAL
CASE
STUDIES



17

ONCOLOGY
CENTERS



150+

MULTIDISCIPLINARY
EXPERTS




1

INTEGRATED
ONCOLOGY NETWORK

www.americanoncology.com

Our facilities across South Asia



We journey with you...

This edition of AOI Oncology Chronicle brings together a diverse set of clinical cases that reflect the evolving landscape of cancer care. Each case has been curated to highlight not only clinical complexity, but also the depth of decision-making and multidisciplinary coordination that underpin effective outcomes.

Across these narratives, there is a clear shift toward precision-led oncology where treatment strategies are increasingly individualized, particularly in high-risk and challenging scenarios.

From organ-preserving radiation approaches to the management of rare malignancies and treatment-related complications, the emphasis remains on delivering care that is both clinically rigorous and outcome-focused.

Equally significant is the role of collaboration. The integration of expertise across specialties continues to be central in navigating complexity and ensuring that each patient benefits from a well-rounded, evidence-based approach.

AOI Oncology Chronicle is intended to serve as a platform for shared clinical insight capturing real-world experiences that reflect how oncology practice is advancing through innovation, discipline, and continuous learning.

We hope this edition provides meaningful perspectives and contributes to ongoing dialogue within the oncology community.



Dileep Mangsuli

Chairman at Cancer Treatment
Services International (CTSI)

Our Leadership Committee



**Dr. Prabhakar
Palacharla**

Regional Chief
Operating Officer,
American Oncology Institute
& Citizens Specialty Hospital
(South Region)

“Excellence in oncology is built through continuous learning, scientific curiosity, and an uncompromising commitment to patient care. Every breakthrough, every successful treatment, and every clinical innovation featured in this edition reflects the extraordinary dedication of our clinicians who continue to set new benchmarks in cancer care. Their passion for advancing medicine and improving outcomes is shaping a stronger, more progressive future for oncology and reinforcing our commitment to delivering exceptional care across every stage of the cancer journey.”



**Dr. Amit
Dhawan**

Regional Chief
Operating Officer,
American Oncology Institute
(Central & East)

“The landscape of oncology continues to evolve at an extraordinary pace, presenting new opportunities to improve outcomes and redefine standards of care. At American Oncology Institute, our clinicians remain at the forefront of this evolution, combining scientific excellence with clinical expertise to deliver innovative, patient-centred care. This edition of AOI Chronicle celebrates their remarkable achievements and reflects our unwavering commitment to advancing oncology through knowledge, collaboration and innovation one breakthrough, one patient and one milestone at a time.”



**Dr. Neeraj
Bishnoi**

Regional Chief
Operating Officer,
American Oncology Institute
(North)

“Every advancement in oncology begins with a commitment to improve a patient’s tomorrow. At American Oncology Institute, our greatest strength lies in the expertise and commitment of our clinicians. Every milestone featured in this edition represents countless hours of research, precision, collaboration and an unwavering focus on patient outcomes. As oncology continues to evolve, our teams remain at the forefront of adopting advanced therapies and pioneering clinical excellence that is transforming cancer care. We extend our sincere appreciation to every clinician whose dedication continues to elevate the oncology spectrum and reinforce our promise of delivering world-class cancer care.”



**Dr. Hrushikesh
Rameshrao
Phate**

Zonal Director,
American Oncology Institute
(Nagpur & Raipur)

“Exceptional oncology care is never the work of an individual, it is the result of collective expertise, multidisciplinary collaboration and an unwavering commitment to excellence. Every breakthrough, every complex case and every clinical milestone featured in this edition reflects the dedication of our clinicians who continue to elevate the standards of cancer care. Their pursuit of innovation and academic excellence reinforces our vision of delivering world-class oncology to every patient we serve. Together, we continue to raise the standard of oncology services across Maharashtra and Chhattisgarh.”

Editorial Committee



Mr. Faisal Siddiqui

Vice President &
Chief Operating Officer,
Processes

“Advances in oncology today call for more than individual expertise – they require teams to come together around proven evidence and shared learning. When evidence – based thinking becomes part of everyday practice and insights are openly exchanged across clinicians and our units, care becomes more consistent and outcomes more predictable.

This not only minimizes variation but also nurtures a culture where excellence is collectively owned. In doing so, we build greater trust with patients, deliver better results and create lasting value across our entire organization.”



Dr. Vibhor Gupta

Director
Medical Operations &
Quality (Oncology), South Asia

“It is my privilege to welcome you to the inaugural edition of our clinical newsletter. This publication has been envisioned as a platform to share the remarkable work being undertaken across our hospitals and to celebrate the expertise of our oncology teams.

In this issue, we present a selection of complex and unique cancer cases that demonstrate clinical excellence, multidisciplinary collaboration and innovative problem-solving. These experiences not only highlight successful patient outcomes but also provide valuable learning opportunities for all of us. I thank every contributor and look forward to growing this knowledge-sharing tradition together.”



Dr. Mir Raza Ali Khan

Director
Medical Operations &
Quality (Multi-specialty)
South Asia

“Oncology today demands evidence-based practice, multidisciplinary collaboration, and innovation in diagnostics and therapeutics.

The AOI Oncology Chronicle captures our clinical experiences, treatment insights, and evolving best practices to strengthen cancer care across our network. In India’s growing oncology landscape, this platform advances knowledge for clinicians while empowering patients through shared expertise. I am honoured to be associated with this initiative, reflecting our commitment to clinical excellence and improved patient outcomes.”

Medical Committee



**Dr. Jagdishwar
Goud Gajagowni**
Senior Consultant & National Director
Robotic Onco Surgery,
AOI Hyderabad



Dr. AVS Suresh
Senior Consultant
Medical Oncology & Haematology
AOI Hyderabad



**Dr. Babita
Bansal Singh**
Senior Consultant
Radiation Oncology,
AOI Gurugram



**Dr. Sumeet
Aggarwal**
Senior Consultant
Radiation Oncology,
AOI Hisar



Dr. Satyanker Gupta
Senior Consultant
Medical Oncology,
AOI Jammu



Dr. Deepak Abrol
Senior Consultant
Radiation Oncology,
AOI Jammu



**Dr. Gurvinder
Singh Grewal**
Assistant Professor
Medical Oncology,
AOI Ludhiana



**Dr. Rahul Lal
Chowdary**
Consultant
Radiation Oncology,
AOI Jalandhar



**Dr. Kannan
Maharajan**
Consultant
Radiation Oncology
AOI Coimbatore



Dr. A. I. Singh
Consultant
Hemato Oncology,
AOI Imphal



**Dr. Sreekanth
Kotagiri**
Consultant
Surgical Oncology
AOI Vijayawada, Kanuru



Dr. Vijay Koduru
Consultant
Surgical Oncology
AOI Vijayawada, Kanuru



Dr. Ashish Bhange
Consultant
Radiation Oncology,
AOI Nagpur



Dr. Eshant Inapuri
Consultant
Surgical Oncology
AOI Vijayawada, Kanuru

Feature Case

01

Precision Oncology: The New Frontier in Esophageal Cancer Surgery 08


Dr. Jagdishwar Goud Gajagowni

- | | | | |
|----|---|----|--|
| 02 | Organ Preservation in Renal Cell Carcinoma Using SBRT 10 | 03 | Autologous PBSCT in HIV-Positive Multiple Myeloma 12 |
| 04 | 72-Year-Old Triumphs Over Stage IV Lymphoma 14 | 05 | Metastatic Breast Cancer: A 6-Year Success Story 16 |
| 06 | The "PSA Paradox": When FDG PET/CT Outperforms Traditional Markers 18 | 07 | Successful Management of Stage IV Lung Cancer & Critical Complication 20 |
| 08 | Milestone Alert: First Total Body Irradiation (TBI) 22 | 09 | Leading the Way with Advanced Radiosurgery & Motion Management 24 |
| 10 | Deep Inspiration Breath Hold (DIBH) Protecting the Heart & Lungs 26 | 11 | A Multidisciplinary Triumph over a Giant Maxillary Brown Tumor 27 |
| 12 | Overcoming Treatment Barriers in Advanced Hodgkin's Lymphoma 28 | 13 | Turning the Tide: A Triumph of Precision and Teamwork in Rare Cancer Care 30 |
| 14 | Surgical Excellence: Navigating High-Risk Surgery with Precision 32 | 15 | Sickle Beta Thalassemia and HLH 34 |
| 16 | The Road Not Taken First: Radiotherapy's Triumph in a Defaulted Grade 3 Intraventricular Astrocytoma 36 | | |

Disclaimer: This newsletter is intended for informational and educational purposes only. All images used in this publication are representative and for illustrative purposes only, unless otherwise stated and should not be construed as depicting actual patients, clinical scenarios or outcomes. The content reflects selected clinical, academic, research and organizational updates of American Oncology Institute. The views expressed by individual contributors are their own and do not necessarily represent the official views of American Oncology Institute. Reproduction or distribution of this publication, in whole or in part, without prior written permission is prohibited.

Precision Oncology: The New Frontier in Esophageal Cancer Surgery

A Global Success Story in Hyderabad




In a significant milestone for precision medicine, the American Oncology Institute (AOI), Hyderabad, recently performed a high complexity robotic esophagectomy on a 54-year-old patient from the United States. This case highlights a major shift in cancer treatment: the integration of robotic assisted surgery with Indocyanine Green (ICG) fluorescence guided technology.

The patient, diagnosed with an early-stage adenocarcinoma at the gastroesophageal junction, sought treatment at AOI Hyderabad a Facility now recognized globally for hosting one of the largest series of esophagectomy procedures in India.



**Dr. Jagdishwar
Goud Gajagowni**

Senior Consultant & National Director
Robotic Onco Surgery,
AOI Hyderabad



The Invisible Threat

Small tumours (in this case, only 1.5 cm) often hide beneath the surface, making them nearly invisible to the naked eye during standard surgery. By integrating ICG fluorescence with robotic surgery, we are moving from subjective surgery to objective, image guided precision. This significantly enhances safety and oncological outcomes Dr. Jagdishwar Goud Gajagowni says.

To solve this, the surgical team utilized the Firefly imaging system. By injecting a small dose of ICG directly into the tumour, surgeons were able to see the cancer “glow” bright green in real time. This allowed for perfect localization and ensured that the tumour was removed with safe, clean margins.

Critical Structure Protection

Visualizing the Thoracic Duct and Airway to prevent accidental injury to the lungs and lymphatic system.

The “Triple ICG Strategy”

Redefining Surgical Safety

The AOI team didn’t stop just finding the tumour. They implemented a comprehensive Triple ICG Strategy to safeguard the patient during the Robotic Ivor Lewis esophagectomy.

Tumour Localization

Ensuring 100% Oncological Clearance.


Perfusion Assessment

Real-time monitoring of blood supply to prevent surgical leaks.

Proven Results

A Study of 32 Patients

This wasn’t just a one-time success. A prospective study conducted by the AOI team on 32 patients revealed the transformative power of this objective guidance.



Organ Preservation in Renal Cell Carcinoma Using SBRT

- AOI Jalandhar

American Oncology Institute (AOI), Jalandhar continues to push the boundaries of non-invasive oncology. In a landmark case, a multi-disciplinary team has successfully treated a 62-year-old patient battling Renal Cell Carcinoma (Kidney Cancer) complicated by **Chronic Kidney Disease (CKD)** and **Liver Cirrhosis**, avoiding both the surgeon's knife and lifelong dialysis.



Dr. Rahul Lal Chowdary

Consultant
Radiation Oncology,
AOI Jalandhar

The Clinical Challenge

High Risk, High Stakes

For this specific patient, conventional surgical intervention was not just difficult, it was exceptionally dangerous.

The Risk

Surgical removal of the kidney would likely have triggered total renal failure, necessitating permanent dialysis.

Comorbidity

Pre-existing liver cirrhosis added a secondary layer of high surgical mortality risk.

The Solution

Targeted SBRT

Guided by the successful results of the FASTRACK clinical trials, Dr. Rahul Lal Chowdary, Consultant Radiation Oncologist opted for Stereotactic Body Radiotherapy (SBRT).

What is SBRT?

It is an advanced radiation technique that delivers high-precision, potent doses to the tumor while sparing healthy surrounding tissue.

Frequency

Only 3 short sessions over a single week.

Invasive level

Zero cuts, zero blood loss.

Outcome

10 months post treatment, the patient remains clinically stable with preserved kidney function.



Expert Voices

This is not just about curing cancer; it is about preserving dignity, organ function, and quality of life. Radiation is no longer the last resort it's the new frontier in organ-preserving cancer care.

Dr. Rahul Lal Chowdary, Radiation Oncologist, AOI Jalandhar states, In cases where surgery is not an option due to compromised organ function, targeted radiation therapy allows us to treat malignancy while protecting the kidney. Outcomes like these reinforce the importance of patient-centric, organ-preserving approaches.



C4Y
PL1
D1Y

Autologous PBSCT in HIV-Positive Multiple Myeloma

- AOI Imphal

At American Oncology Institute (AOI), Imphal, a 54-year-old male, known retro positive case for more than 20 years, receiving antiretroviral therapy with Abacavir, Lamivudine and Dolutegravir with good adherence. The patient presented severe back pain for 3 weeks in August 2025. The patient had comorbid T2DM and hypertension. This report highlights a significant clinical achievement in the management of Multiple Myeloma within the context of chronic HIV infection.



Dr. A. I. Singh

Consultant
Hemato Oncology,
AOI Imphal



Key takeaways from this case include:

The Invisible Threat

Patient presented with Stage III Multiple Myeloma (ISS) and severe renal dysfunction (S. Creatinine 4.4 mg/dl) despite a 20-year history of well-managed HIV.

The CD4 Milestone

A critical factor in moving toward transplant was the recovery of the CD4 count. Starting at <100 cells/ μL , the patient reached a safe threshold of 255 cells/ μL through effective induction therapy and continued ART.

Successful Mobilization

Using G-CSF and Plerixafor, a robust stem cell yield of 6.15×10^6 CD34⁺ cells/kg was achieved.

Rapid Engraftment

Despite the complexities of comorbid T2DM, hypertension, and HIV, neutrophil engraftment occurred on Day +9 and platelet engraftment on Day +11. This case demonstrates that with a multidisciplinary approach and careful viral management, Autologous PBSCT is a safe and effective “standard of care” option even for patients with long-term HIV-induced immunosuppression.

72-Year-Old Triumphs Over Stage IV Lymphoma

- AOI Sri Ganganagar

In a significant milestone for geriatric oncology in India, the American Oncology Institute (AOI), Sri Ganganagar, recently celebrated the successful treatment of an advanced-stage lymphoma patient. This case serves as a powerful reminder that age and stage are no longer insurmountable barriers to effective cancer care.

The Challenge

Advanced High-Grade DLBCL

In March 2024, a 72-year-old patient presented with a large, firm mass (10 x 8 cm) on the nape of the neck. While painless, the swelling restricted mobility and was accompanied by noticeable weight loss.



Dr. Navaneeth Reddy

Medical & Hemato-Oncology,
AOI Sri Ganganagar



Diagnostic evaluations revealed a complex clinical picture:

Diagnosis

High-grade Diffuse Large B-cell Lymphoma (DLBCL).

Biopsy Markers

CD20+, CD45+, and a Ki-67 index of 60–70%, indicating rapid cell proliferation.

Staging

PET-CT scans confirmed Stage IV lymphoma, with FDG-avid deposits spreading across the chest wall, thighs, pelvic muscles and abdominal wall.

Breaking the “Elderly Barrier”

There is a common misconception that aggressive chemo-immunotherapy is too taxing for elderly patients. However, the medical team at AOI tailored a strategy focused on CD20-directed therapy combined with specialized chemotherapy.

“This case highlights the effectiveness of modern chemo-immunotherapy in elderly patients,” says Dr. Navaneeth Reddy, Medical & Hemato-Oncologist at AOI. “Contrary to common belief, well-tailored regimens can lead to successful outcomes even in advanced stages.”

Why This Matters for India

The incidence of non-Hodgkin lymphoma (NHL) is rising across India, often linked to urban lifestyle shifts and late-stage diagnoses. This success story underscores three critical pillars of modern Indian healthcare.

Early Intervention

Recognizing symptoms like persistence, painless swellings and unexplained weight loss.

Tailored Care

Customizing treatment based on comorbidities and ECOG performance scores rather than age alone.

Global Standards

Access to American and European guideline-based therapies is now a reality in India, reaching patients across all socioeconomic backgrounds. This breakthrough reinforces AOI’s commitment to providing world-class, internationally aligned care. For patients and families navigating a lymphoma diagnosis, this case stands as a beacon of hope. Advanced cancer is treatable, and age is not a contraindication for recovery.

Metastatic Breast Cancer: A 6-Year Success Story - AOI Jammu

At American Oncology Institute (AOI), Jammu, we believe that no diagnosis is too complex when met with clinical excellence and advanced technology. Today, we celebrate a remarkable milestone a patient who has remained cancer free for six years after battling metastatic breast cancer.

The Challenge

A Complex Diagnosis

A 50-year-old female patient arrived at our facility seeking hope during an incredibly difficult period. Following a comprehensive evaluation by Dr. Satyanker Gupta (Sr. Con. Medical Oncology), she was diagnosed with metastatic breast cancer.

As the journey progressed, the clinical challenge intensified. Further investigations revealed that the cancer had spread, manifesting as metastases in both the brain and the liver.

Strategy

A Multidisciplinary Approach

To combat this advanced stage of the disease, our multidisciplinary team engineered a personalized, aggressive treatment protocol. This integrated plan combined systemic and targeted interventions.

Targeted Therapy

Precision medicine to attack specific cancer cells.

Chemotherapy

To aggressively manage the systemic spread.

Hormonal Therapy

To block the hormones fueling the cancer growth.

Advanced Precision

SRS & SBRT

Addressing the spread to the brain and liver required the highest level of technical expertise. Our Radiation Oncology team, led by Dr. Deepak Abrol (Sr. Consultant, Radiation Oncology), utilized cutting-edge technology to deliver pinpoint treatment.



Dr. Satyanker Gupta

Senior Consultant
Medical Oncology,
AOI Jammu



Dr. Deepak Abrol

Senior Consultant
Radiation Oncology,
AOI Jammu

Stereotactic Radiosurgery (SRS)

For the non-invasive treatment of brain metastases.

Stereotactic Body Radiotherapy (SBRT)

For highly precise targeting of liver lesions.

The Outcome

Six Years' Cancer-Free

The synergy of expert clinical judgment and state-of-the-art technology led to a remarkable recovery. Today, six years later, the patient shows no evidence of disease (NED).

"This case is a testament to the power of timely intervention and a reminder that even in the most complex metastatic cases, world-class care can lead to life-changing outcomes."

At AOI Jammu, we remain committed to pushing the boundaries of oncology to ensure every patient has the best possible chance at a healthy, cancer-free future.





The “PSA Paradox”: When FDG PET/CT Outperforms Traditional Markers

– AOI Sri Ganganagar

The Case: An Aggressive Phenotype Hiding in Plain Sight

At American Oncology Institute (AOI), Sri Ganganagar, a recent clinical case involving a 73-year-old male presenting with lower urinary tract symptoms (LUTS) has highlighted a critical diagnostic challenge in prostate cancer management. Despite a PSA of only 3.33 ng/ml a level often considered low-risk initial MRI imaging revealed alarming skeletal metastases, prompting a deeper metabolic investigation via 18F-FDG PET/CT.



Dr. Anjali Meena

Consultant
Nuclear Medicine
AOI Sri Ganganagar

Imaging Findings

The FDG PET/CT scan provided a comprehensive map of a highly aggressive disease state that traditional markers failed to fully capture.

Primary Site

An intensely FDG-avid, heterogeneously enhancing mass involving the entire prostate gland.

Rare Soft-Tissue Deposits

Unusual metastatic involvement was identified in the paravesical and pararectal spaces, as well as the penile shaft, a highly rare site for secondary deposits.

The Diagnostic Dilemma


A localized FDG-avid lesion in the parotid gland with regional nodal involvement was detected. This raises the clinical suspicion of either an extremely rare metastatic site or a synchronous dual primary malignancy.

Clinical Analysis

The Neuroendocrine Suspicion

The stark contrast between the low PSA levels and the high FDG avidity is a clinical “red flag.” Typically, prostate cancer cells are well differentiated and rely on fatty acid metabolism rather than glucose.

However, when a tumour demonstrates high glycolytic activity alongside low PSA production, it suggests a dedifferentiated or biologically aggressive phenotype, such as: Small-cell carcinoma of the prostate.



Neuroendocrine differentiation

- High-grade Gleason patterns.
- The Evolving Role of FDG PET/CT in Prostate Cancer
- While 18F-PSMA PET/CT remains the gold standard for staging and recurrence due to its specificity, this case underscores the indispensable “niche” role of FDG imaging.

When to consider FDG PET/CT

Castration Resistant Disease (CRPC)

Identifying clones that have evolved beyond.

PSMA-Negative Lesions

In “flip-flop” scenarios where lesions are visible on FDG but not PSMA, indicating a loss of differentiation and a poorer prognosis.

Treatment Stratification


Assessing suitability for Radioligand Therapy; high FDG uptake in PSMA-negative zones often predicts a diminished response to targeted therapy.

The Bottom Line

This case serves as a powerful reminder that PSA is not a universal barometer for disease burden. In the presence of aggressive variants, FDG PET/CT provides a whole-body assessment that can uncover unexpected synchronous malignancies and rare metastatic sites, ultimately guiding more aggressive or systemic therapeutic interventions.

Key Takeaway

When the clinical picture doesn't match the PSA, look to the glucose. High FDG avidity in prostate cancer is a hallmark of high-grade transformation and requires a pivot in management strategy.



Successful Management of Stage IV Lung Cancer & Critical Complications

- AOI Ludhiana

In a significant milestone for our oncology department, American Oncology Institute (AOI), Ludhiana, our multidisciplinary team recently managed a complex Stage IV lung cancer case complicated by life threatening treatment related to emergencies. This case serves as a testament to the power of rapid clinical intervention and integrated specialist care.



**Dr. Gurvinder
Singh Grewal**

Assistant Professor
Medical Oncology,
AOI Ludhiana

Case Presentation

The patient, a 60-year-old male, presented with Stage IV malignant neoplasm of the lung (T2b, N3, M1). Having been under observation since 2020 for progressive lymphadenopathy, advanced diagnostic evaluations including PET-CT and biopsy confirmed a primary small cell neuroendocrine carcinoma.

The clinical picture was further complicated by

- Extensive lymph node metastasis.
- Pleural and pericardial effusion.
- Suspected secondary lymphoproliferative disorder identified via FNAC.
- Treatment Strategy & Response.

Under the guidance of Dr. Gurvinder Singh Grewal (Assistant Professor, Medical Oncology), a robust therapeutic regimen was initiated.

Chemotherapy

Etoposide and Carboplatin.

Immunotherapy

Serplulimab.

Initial results were highly encouraging, showing a significant reduction in lymph node size, confirming the efficacy of the selected protocol against the primary malignancy.

Managing Critical Complications

The recovery journey was marked by two life-threatening events that required immediate, high-stakes intervention.

Cardiac Tamponade

The patient developed severe pericardial effusion. Our team performed an urgent pericardial drainage to relieve pressure on the heart and restore hemodynamic stability.

Immune-Related Adverse Event (irAE)

The patient experienced immunotherapy-induced encephalitis. This rare neurological complication was successfully reversed using high-dose corticosteroids and Rituximab.

Current Status & Clinical Takeaways

Today, the patient is stabilized. His cardiac function is excellent, with a Left Ventricular Ejection Fraction (LVEF) of 60%, and only mild pericardial effusion persists.

This case underscores that in the era of advanced immunotherapy, success depends not just on the drugs we administer, but on our ability to monitor and manage the complex immune responses they trigger.

Key Lessons:

Vigilance

Early identification of irAEs (like encephalitis) is vital for survival.

Collaboration

Seamless coordination between Oncology, Cardiology, and Critical Care saved this patient's life.

Innovation

Utilizing advanced therapies like Serplulimab can yield results even in systemic, high-stage disease. Our hospital remains committed to pushing the boundaries of cancer care, ensuring that even the most challenging scenarios lead to hopeful outcomes.

Milestone Alert: First Total Body Irradiation (TBI)

- AOI Gurugram

We are thrilled to announce a significant clinical breakthrough at Aarvy Healthcare, in collaboration with the American Oncology Institute (AOI), Gurugram. Our Radiation Oncology team reached a new pinnacle in patient care by successfully delivering the facility's first Total Body Irradiation (TBI). This procedure served as a vital conditioning regimen for a patient undergoing a Bone Marrow Transplant.

What Makes TBI a Milestone?

Total Body Irradiation is a highly specialized technique that demands more than just advanced technology, it requires an extraordinary level of human expertise. The procedure is a critical step in preparing a patient's body for a transplant, necessitating.



**Dr. Babita
Bansal Singh**

Senior Consultant
Radiation Oncology,
AOI Gurugram



Meticulous Planning

Customizing radiation doses ensure maximum efficacy.

Technical Precision

Delivering treatment with submillimeter accuracy.

Multidisciplinary Synergy

Seamless coordination across various medical specialties.

A True Team Effort

This achievement was made possible by the unwavering dedication of our diverse clinical and administrative teams. We extend our deepest gratitude and congratulations to our Radiation Oncologists & Transplant Physicians, Medical Physicists & Radiation Technologists, Nursing Staff & GDAs and Hospital Administration.



This milestone further strengthens our commitment to delivering advanced, comprehensive, and patient-centric cancer care.

By integrating cutting edge technology with a collaborative spirit, we continue to push the boundaries of what is possible in oncology, bringing hope and healing to our patients and their families.



Leading the Way with Advanced Radiosurgery & Motion Management

- AOI Hisar

At American Oncology Institute (AOI), Hisar, we continue to push the boundaries of oncological excellence. As the only centre in the region equipped with high-end Linear Accelerator technology, we are proud to offer life-changing, non-invasive treatment options that were previously unavailable in Hisar.

This year, our clinical team successfully performed 3 SRS, 5 SBRT, 5 SRT, and 10 DIBH cases, marking a new era of precision medicine for our community.




**Dr. Sumeet
Aggarwal**

Senior Consultant
Radiation Oncology,
AOI Hisar

Stereotactic Radiosurgery (SRS/SBRT/SRT)

The Non-Surgical “Knife”

When cancer spreads (Metastasis) to sensitive areas like the brain or liver, traditional surgery is often too risky. Our Stereotactic procedures provide a powerful alternative, delivering ultra-high doses of radiation with pinpoint accuracy to “kill” cancer cells while sparing healthy tissue.



Why it's a Game Changer

Single Day Recovery: Often completed in a single sitting as a daycare procedure.

Surgical Precision: Results are comparable to advanced surgical outcomes without the incisions.

Minimal Interruption: Patients can continue their systemic treatments (like chemotherapy) without delay.


Clinical Highlights

Successfully treated with SRT (21 Gy in a single fraction).

Ca Ovary with Brain Mets:
Achieved targeted control with SRT (21 Gy in a single fraction).


Recurrent BOT: Managed complex recurrence with SBRT (25 Gy in 5 fractions).

Ca Lung with Liver Mets:
Targeted liver metastasis with SBRT (50 Gy in 5 fractions).



Deep Inspiration Breath Hold (DIBH) Protecting the Heart & Lungs

– AOI Hisar



Treating left-sided breast cancer or thoracic tumours presents a unique challenge

The heart and lungs move with every breath. DIBH is our advanced motion-management protocol that synchronizes radiation delivery with the patient's breathing cycle.

The Benefits


- **Heart Protection:** Significantly reduces radiation exposure to the heart and healthy lung tissue.
- **Maximum Accuracy:** Ensures the tumour is hit at the exact same position every time.
- **Reduced Side Effects:** Minimizes long-term complications for thoracic cancer survivors.

A New Milestone in Cancer Care for Hisar

We are proud to be Hisar's first and only center to offer these advanced procedures, bringing world-class Oncology closer to our community.

Clinical Highlights

- **Left-sided Breast Cancer:** Received precise treatment of 50 Gy over 20 fractions with minimal cardiac exposure.
- **Ca Lung:** Successfully managed with DIBH (50 Gy in 25 fractions) to ensure maximum lung sparing.



A Multidisciplinary Triumph over a Giant Maxillary Brown Tumor

- AOI Raipur

At American Oncology Institute (AOI), Raipur, we recently encountered a clinical challenge that perfectly illustrates the power of metabolic diagnosis over aggressive surgical intervention. A 31-year-old man presented with a massive, three-year-old growth in his upper jaw. The lesion had caused recurrent, severe bleeding dropping his haemoglobin to a critical 5.8 g/dL and had left him fearing the facial disfigurement of a previously recommended total maxillectomy.

The Diagnostic Breakthrough

While the jaw lesion appeared oncological, clinical suspicion led to a deeper metabolic investigation.

The Results were telling:

Severe Hypercalcemia: 12.7 mg/dL

Elevated PTH: 640 pg/mL (Primary Hyperparathyroidism)

Sestamibi Scan: Localized a left inferior parathyroid adenoma.

The "tumour" was not a primary bone malignancy but a Brown Tumour of the Maxilla a rare, non-neoplastic manifestation of hyperparathyroidism.



Dr. Saurabh Jain

Consultant
Surgical Oncology,
AOI Raipur



Overcoming Treatment Barriers in Advanced Hodgkin's Lymphoma

- AOI Nagpur

At American Oncology Institute (AOI), Nagpur, we are pleased to share a remarkable case of clinical resilience involving an 18-year-old male from rural Maharashtra. His journey highlights the critical importance of timely diagnosis and the impact of a coordinated, multidisciplinary oncology approach when facing complex medical comorbidities.



Dr. Ashish Bhange

Consultant
Radiation Oncology,
AOI Nagpur

The Challenge: A Complicated Clinical Picture


The patient initially presented with a persistent swelling in the right neck. Unfortunately, due to inconclusive initial diagnostics (FNAC) and subsequent alternative treatments, the diagnosis was delayed. By the time he reached our care, the clinical picture had worsened significantly and presented with Severe Hepatic Dysfunction. The patient developed jaundice with a total bilirubin >22 mg/dl, later confirmed via biopsy as Drug-Induced Liver Injury (DILI).

Oncological Diagnosis: An excision biopsy of the lymph node finally confirmed Classical Hodgkin's Lymphoma (Stage IIB).

The Multidisciplinary Approach

Standard chemotherapy protocols were high-risk due to the patient's severely deranged liver functions. A collaborative strategy was implemented:

1. Gastroenterology: Managed the acute liver injury to stabilize the patient for systemic therapy.
2. Haemato-Oncology: Initiated a modified regimen of Gemcitabine chemotherapy, tailored to accommodate his hepatic limitations.
3. Radiation Oncology: After four cycles of chemotherapy showed disease progression, the team pivoted to a localized, high-precision strategy.





Precision Intervention

The Radiation Oncology team planned and delivered: Involved Field Radiation Therapy (IFRT). Using state-of-the-art Image Guided Radiation Therapy (IGRT), we delivered a dose of 36Gy in 20 fractions. Despite the poor initial prognosis and limited systemic options, the patient tolerated the treatment exceptionally well.

Outcome and Follow-up

The post-treatment PET-CT revealed a complete metabolic and morphological response.

Current Status

Five months of post-treatment, the patient remains disease-free and is living a healthy life. He continues regular follow-ups for both his oncological status and the ongoing management of his liver health.

Key Takeaways

The Danger of Delay

This case serves as a stark reminder of the consequences of delayed diagnosis in highly curable cancers like Hodgkin's Lymphoma.

Comprehensive Care

Success was made possible through the availability of a dedicated oncology team and advanced treatment technologies.

Clinical Excellence

Achieving a complete response in the face of life-threatening hepatic dysfunction is a testament to the power of personalized, multidisciplinary medicine. This success story reinforces our commitment to providing world-class oncological care, even in the most challenging circumstances.

Turning the Tide: A Triumph of Precision and Teamwork in Rare Cancer Care

- AOI Hyderabad



The Challenge: A Race Against an Aggressive Rarity

In February 2026, American Oncology Institute (AOI), Hyderabad, faced a daunting clinical challenge. A 32-year-old patient presented with a second recurrence of Follicular Dendritic Cell Sarcoma an ultra-rare malignancy representing less than 0.4% of all soft tissue sarcomas.

Despite two previous surgeries in 2025, the disease returned with unprecedented aggression. The patient arrived in a life-threatening state, characterized by:



Dr. AVS Suresh

Senior Consultant
Medical Oncology & Haematology
AOI Hyderabad

Massive Tumour Burden

A pelvic mass measuring 19 cm.

Critical Instability

Severe anemia and active tumour related bleeding.

Organ Infiltration

Deep involvement of multiple pelvic structures.
The Intervention: Stabilize, Diagnose, Decide.

The multidisciplinary team at AOI Hyderabad didn't just see a patient; they saw a critical window for intervention. The response was immediate and three-pronged.

Precision Intervention

01

While blood transfusions addressed life-threatening anemia, advanced imaging mapped the tumour's vascularity to identify bleeding risks, successfully avoiding the high mortality risk of emergency surgery.

Pathological Precision

02

Time was of the essence. Our pathology department delivered a rapid turnaround, utilizing a specialized Immunohistochemistry (IHC) panel including CD21, CD23 and CD35 to confirm the FDCS diagnosis and lock in the treatment pathway.

The Gentle to-Aggressive Strategy

03

Recognizing the patient's fragility, the Medical Oncology team opted for a sophisticated, stepwise chemotherapy escalation:

Phase 1: Low-dose Cyclophosphamide to arrest growth without overwhelming the patient's system.

Phase 2: Transition to Gemcitabine + Docetaxel (GemTax) once the patient was hemodynamically stable.

The Result

From Inoperable to Recovery

The impact of this calibrated approach was nothing short of remarkable. The massive tumour was effectively down staged, shrinking from its original size to a much more manageable size.

This transformation turned an inoperable, life-threatening situation into a pathway with curative intent.

The patient is now moving into the next phase of his journey: Radiotherapy to further consolidate the tumour, followed by definitive surgery to remove the remaining mass.

The AOI Advantage: Multidisciplinary Synergy

This success story is a testament to the power of our Tumour Board philosophy. By uniting specialists across Pathology, Radiology, Medical Oncology, Radiation Oncology, and Surgery, we ensured that every decision was evidence-based and patient centric. At AOI, we believe that rare doesn't mean untreatable. Through precision medicine and seamless teamwork, we continue to redefine what is possible in cancer care. For more clinical insights or to refer a case, visit our website or contact the AOI Hyderabad Tumour Board.

Surgical Excellence: Navigating High-Risk Surgery with Precision

- AOI Vijayawada, Kanuru

At the American Oncology Institute (AOI), Vijayawada, our surgical oncology team recently achieved a significant clinical milestone, demonstrating that even the most complex cases can have successful outcomes when met with expertise and advanced technology.



**Dr. Sreekanth
Kotagiri**

Consultant
Surgical Oncology
AOI Vijayawada, Kanuru



**Dr. Vijay
Koduru**

Consultant
Surgical Oncology
AOI Vijayawada, Kanuru



**Dr. Eshant
Inapuri**

Consultant
Surgical Oncology
AOI Vijayawada, Kanuru



The Challenge: A High-Risk Clinical Profile

Our patient, 54-year-old Satyavathi, presented with a two-month history of progressive difficulty swallowing solids. Investigations confirmed Squamous Cell Carcinoma (SCC) in the lower third of the esophagus. While the cancer itself required aggressive intervention, the patient's underlying health presented a formidable hurdle.

Post-COVID Lung Complications

The patient suffered from severe respiratory impairment.

Compromised Lung Function

Pulmonary Function Tests revealed an FEV1 of 30% and an FVC of 31%, categorizing her as a very high-risk surgical candidate.

The Strategy

Neoadjuvant Care & Advanced Surgery

Following a PET CT evaluation, the clinical team initiated Neoadjuvant Chemoradiotherapy (NACTRT) to shrink the tumour before surgery.

In February 2026, a multidisciplinary team led by Dr. Eshant Inapuri, Dr. Vijay Koduru, and Dr. Sreekanth Kotagiri performed a Laparoscopic Three-Field Esophagectomy. This complex procedure involved:

Removal of the cancerous portion of the esophagus.

Stomach Conduit Pull-up

Reconstructing the digestive path using the patient's stomach.

Minimally Invasive Approach

Utilizing laparoscopy to reduce physical trauma and speed up recovery critical for a patient with compromised lung health.



The Outcome

Despite the high-risk status, the surgery was uneventful. Thanks to the precision of the laparoscopic technique and dedicated post-operative care, the patient's recovery was smooth. Satyavathi was successfully discharged on Post-Operative Day 8 (POD-8).

This case highlights our commitment to pushing the boundaries of surgical oncology. By combining advanced laparoscopic techniques with careful perioperative management, we can offer lifesaving surgeries to patients who might otherwise be considered too high risk.

Sickle Beta Thalassemia and HLH

- AOI Hyderabad

Sickle beta thalassemia is a challenging compound hemoglobinopathy. By combining the cellular instability of Sickle Cell Disease (SCD) with the reduced haemoglobin production of Beta Thalassemia, patients are often caught in a cycle of Vaso-occlusive crises (VOC), chronic hemolysis and multi-organ dysfunction.

While common complications like Acute Chest Syndrome are well-known, this case highlights a more elusive and life-threatening condition. Secondary Hemophagocytic Lymphohistiocytosis (HLH).

Case Study: The Diagnostic Challenge

Patient Presentation

A 22-year-old male was admitted following a history of fever, jaundice, and generalized abdominal pain. Despite receiving initial blood transfusions at a peripheral facility, his condition remained unstable upon arrival.



Dr. AVS Suresh

Senior Consultant
Medical Oncology & Haematology
AOI Hyderabad

Clinical Findings:

Vitals

Tachycardic (PR 112/min) and febrile.

Physical

Deep icterus (jaundice), pallor, and significant hepatosplenomegaly.

Lab Investigations

Severe anemia (Hb 4.9 g/dL), fluctuating leukocyte counts, hyperbilirubinemia, and hypertriglyceridemia.

Marking Point:

While initial treatment focused on standard VOC protocols (hydration, oxygen, and opioids), the patient's persistent fever and worsening cytopenias (lowered blood cell counts) suggested something beyond a typical crisis. HPLC confirmed the underlying Sickle Beta Thalassemia, but the systemic inflammatory response pointed elsewhere.

Identifying Secondary HLH

HLH is a hyperinflammatory syndrome where the immune system enters a "cytokine storm," often triggered by infection or severe inflammatory states like a VOC. In this case, the clinical team utilized the H-score to bridge the diagnostic gap.

Diagnostic Insight

With an H-score of 205, the probability of HLH was remarkably high. This score accounts for temperature, organomegaly, cytopenias, triglycerides, fibrinogen, and ferritin levels.

Management & Clinical Outcomes

The patient's recovery hinged on a dual-track intervention strategy:

1. Red Cell Exchange (RCE)

Performed to rapidly reduce the concentration of HbS (sickle hemoglobin), curbing the underlying sickling process and improving oxygenation.

2. Immunosuppression

Once HLH was suspected, the patient was started on Dexamethasone.

Following the initiation of steroids, the fever subsided rapidly, and the patient's clinical markers showed significant improvement.

Key Takeaways for the Clinical Team

- **Think Beyond the Crisis**
Overlapping symptoms (fever, cytopenias) often mask HLH in sickle cell patients. If a patient isn't responding to standard transfusion and hydration, re-evaluate.
- **The Utility of the H-Score**
Early calculation of the H-score can be lifesaving in a critical care setting.
- **Prompt Intervention**
Combining Red Cell Exchange with early steroid therapy can halt the progression of hyperinflammation and improve survival rates.

Conclusion

This case serves as a vital reminder that a multidisciplinary approach is essential. Recognizing the rare secondary complications of hemoglobinopathies is the difference between a routine recovery and a fatal outcome.



The Road Not Taken First: Radiotherapy's Triumph in a Defaulted Grade 3 Intraventricular Astrocytoma

- AOI Coimbatore

A recent multidisciplinary success story at our American Oncology Institute (AOI), Coimbatore, underscores a critical lesson in neuro-oncology: while alternative pathways or systemic therapies may temporarily delay standard protocols, well-timed, aggressive radiation therapy remains an indispensable pillar in managing high-grade central nervous system (CNS) malignancies.

The Challenge: A Rare Presentation

In June 2024, a 29-year-old woman presented with classic signs of increased intracranial pressure: headache, vomiting, and gait disturbance.


Neuroimaging revealed a lesion in the intraventricular septum. Primary intraventricular high-grade glial tumors are exceptionally rare, constituting a tiny fraction of all CNS malignancies. Their location poses immense diagnostic hurdles and profound surgical risks.

The patient underwent a left frontal craniotomy with subtotal excision. Histopathology confirmed a high-stakes diagnosis: WHO CNS Grade 3 Astrocytoma, NOS.



**Dr. Kannan
Maharajan**

Consultant
Radiation Oncology
AOI Coimbatore



Tumor Profile:

Molecular Status: ATRX loss

Proliferation Index: Ki-67 of 8–10%

The Deviation: Alternative Path & Progression.

Following surgery, standard care dictated adjuvant radiotherapy. However, the patient defaulted on this recommendation. She opted instead to pursue integrated alternative therapies combined with a systemic regimen of: Temozolomide (22 cycles) Bevacizumab.

While this regimen managed the disease for a time, the high-grade nature of the astrocytoma inevitably took over. By July 2025, the patient developed new-onset seizures. By October 2025, a CT scan confirmed residual and recurrent supra- and intraventricular disease-causing ventricular obstruction.

The Turning Point: Multidisciplinary Intervention

Referring to our institution in late 2025, the patient's case was immediately brought before our Multidisciplinary Tumor Board (MTB). The board's collective deliberation proved to be the decisive turning point. Balancing the advanced state of the disease with the patient's functional status, the MTB

formulated a nuanced, aggressive plan: palliative-intent radiotherapy delivered with curative-level dosing.

The clinical team executed a precise, two-phase whole ventricular radiation therapy (RT) plan.

The Outcome & Key Takeaways

The clinical response was remarkable. Upon completion of her radiation treatment, the patient was entirely asymptomatic. This case serves as a powerful testament to three core principles in modern oncology:

Rare Tumor Awareness:

The clinical response was remarkable. Upon completion of her radiation treatment, the patient was entirely asymptomatic.

This case serves as a powerful testament to three core principles in modern oncology:

The Power of the MTB:

Collaborative, cross-specialty decision-making is vital when navigating atypical, high-stakes tumor progression.

The Power of Radiation:

Even when delayed by standard defaults, precisely targeted radiotherapy can achieve profound local control and symptom resolution.

Your body could be
keeping secrets from you,
Know them before it's too late.

mila

Let this be about **her.**

-  **Breast Cancer**
-  **Uterine Cancer**
-  **Cervical Cancer**
-  **Ovarian Cancer**

Scan to know more



WORLD
NO TOBACCO DAY

 **AOI**[®]
AMERICAN ONCOLOGY INSTITUTE
PRECISION CANCER CARE

Nearly

1 IN 10

Indian adolescents
have experimented with
tobacco before the
age of 10.

Educate Early.
Build a No Tobacco
Generation.

The "No Tobacco"
Conversation
Starts at Home.

Source: National Library of Medicine
<https://pmc.ncbi.nlm.nih.gov/articles/PMC3103155/>

Scan to watch the video



American Oncology Institute · #ProtectBeforeItBegins

Introducing

Cancer Survivors Program

Celebrating Courage. Honouring Journeys.
Inspiring Hope

Our Promise



Compassionate
Care



Community
Support



Healing &
Wellness



Strength &
Resilience



Hope &
New Beginnings

You are not just a survivor

You are an inspiration

**We Support • We Empower
We Celebrate • We Walk With You**

Scan to know more





**13+ years of oncology excellence in India,
shaped by millions of unique patient stories.**



**Cancer Expert
Opinion**

Comprehensive Cancer Care: Medical, Surgical & Radiation

We, American Oncology Institute (AOI), one of India's leading cancer care networks, have oncology specialists united across our network to make expert treatment accessible. Our **Cancer Expert Opinion Program** is a first-of-its-kind initiative designed to gain clarity. Backed by our oncology ecosystem, it enables an informed review and treatment plan, so that decisions are made with conviction.

					
17 Centres	Multi-disciplinary Cancer Expertise	150+ Cancer Specialists	International Tumor Board	AI-enabled, Centralized Treatment Planning	Standard Treatment Protocols

Getting a Cancer Expert Opinion Program is simple...



Scan to avail
the expert
opinion



Upload your
medical reports
securely (optional)



Appointment
scheduled within
24 hours after review

Our Presence: India: Jammu | Jalandhar | Ludhiana | Hisar | Gurugram | Sri Ganganagar | Kota | Aligarh | Raipur | Imphal | Nagpur
Hyderabad | Vijayawada | Guntur | Coimbatore | Sri Lanka: Colombo



ALL INDIA CRITICAL CARE HOSPITAL RANKING SURVEY 2026

ONCOLOGY NATIONAL MULTI SPECIALITY

NATIONAL SINGLE SPECIALITY



HYDERABAD SINGLE SPECIALITY



SOUTH SINGLE SPECIALITY





FROM INSIGHT TO IMPACT NOW A GUINNESS WORLD RECORD.



Congratulations!

Dr. AVS Suresh

Senior Consultant - Medical Oncology & Hematology,
Convener, AI in Healthcare Education Programme
at NBEMS (Govt. of India)

Proudly Received A Guinness World Record for:

Most viewed session on Artificial Intelligence in Healthcare lesson live streamed
on YouTube in collaboration with NBEMS.

Advancing AI. Elevating Medical Education. Representing India on Global Stage.



25TH
FEBRUARY
2026



17,999
VIEWS



**Proud Moment for
American Oncology Institute &
Citizens Specialty Hospital, Hyderabad**

Advanced Cancer Care. Transforming Outcomes.

American Oncology Institute (AOI) is a leading oncology network delivering comprehensive, evidence-based and compassionate cancer care across India and South Asia.

Our multidisciplinary teams, advanced technology and patient-centric approach empower better outcomes and a higher quality of life for our patients.



17
Centres



Multi-disciplinary
Cancer Expertise



150+ Cancer
Specialists



International
Tumor Board



AI-enabled, Centralized
Treatment Planning



Standard
Treatment Protocols

Our Network

Expanding Access. Enhancing Lives.



- ♦ Jammu
- ♦ Jalandhar
- ♦ Ludhiana
- ♦ Aligarh
- ♦ Hyderabad
- ♦ Kota
- ♦ Gurugram
- ♦ Imphal
- ♦ Nagpur
- ♦ Hisar (1 & 2)
- ♦ Raipur
- ♦ Vijayawada
- ♦ Guntur
- ♦ Coimbatore
- ♦ Sri Ganganagar
- ♦ Colombo (Sri Lanka)

Scan to
access our
website ►



Stay Connected



www.americanoncology.com

Great
Place
To
Work®

Certified

APR 2026 - APR 2027

INDIA